Related Experiment Video

Updated: Aug 23, 2026

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
07:59

Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration

Published on: April 4, 2022

Glycoprotein IIb/IIIa antagonists in acute coronary syndromes: where are we now?

Andrew Maree1, Desmond J Fitzgerald

  • 1Department of Clinical Pharmacology, Royal College of Surgeons in Ireland, Dublin, Ireland.

Seminars in Vascular Medicine
|June 17, 2004
PubMed

Insights

Glycoprotein (GP) IIb/IIIa antagonists show benefit in percutaneous coronary intervention but disappointing results in acute coronary syndromes (ACS). Oral GP IIb/IIIa antagonists in ACS trials were linked to increased mortality, possibly due to dosing and variable patient responses.

Area of Science:

  • Cardiovascular Medicine
  • Hematology
  • Pharmacology

Background:

  • Acute coronary syndromes (ACS) involve vascular inflammation, coronary constriction, and thrombus formation.
  • Platelet adhesion and aggregation are critical to these processes, with the integrin glycoprotein (GP) IIb/IIIa receptor playing a key role.
  • While GP IIb/IIIa antagonists benefit percutaneous coronary intervention, their efficacy in ACS is questionable.

Purpose of the Study:

  • To evaluate the role and efficacy of glycoprotein (GP) IIb/IIIa antagonists in the context of acute coronary syndromes (ACS).

Main Methods:

  • Review of clinical trial data for oral GP IIb/IIIa antagonists in ACS patients.
  • Analysis of factors contributing to suboptimal outcomes, including drug dosing, pharmacodynamics, and patient variability.

Main Results:

  • Trials of oral GP IIb/IIIa antagonists in ACS were associated with increased mortality.
  • Suboptimal receptor occupancy, incomplete platelet aggregation inhibition, and potential proinflammatory effects may contribute to poor outcomes.
  • Variable patient responses suggest population heterogeneity impacting drug efficacy.

Conclusions:

  • Current oral GP IIb/IIIa antagonists have disappointing results in ACS, unlike their use in percutaneous coronary intervention.
  • Challenges in achieving optimal and consistent therapeutic effects necessitate further research into alternative strategies or improved drug delivery for ACS management.

More Related Videos

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader07:13

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader

Published on: May 24, 2024

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Acute Coronary Syndrome V: Nursing Management01:26

Acute Coronary Syndrome V: Nursing Management

Nursing Assessment:Nursing management of acute coronary syndrome (ACS) involves taking the patient's history, focusing on primary complaints such as chest pain, dyspnea, and excessive sweating (diaphoresis), as well as other symptoms like back or jaw pain, nausea, vomiting, palpitations, dizziness, and fatigue. The nurse also reviews the patient's history of cardiac events, risk factors such as hypertension, diabetes, smoking, family history, and current medications.In the objective assessment,...